Article
The prognostic values of systemic immune-inflammation index and derived neutrophil-lymphocyte ratio in EGFR-mutant advanced non-small cell lung cancer.
Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners - 1 Jan 2021
Yucel Sebnem, Bilgin Burak
Abstract excerpt
INTRODUCTION: Targeted therapy is the main treatment option for oncogene-addicted non-small cell lung cancer (NSCLC). It is known that inflammation can affect survival. Therefore, we aimed to evaluate the effect of host inflammation on survival and treatment outcome by using the derived neutrophil-lymphocyte ratio (dNLR) and systemic immune-inflammation index (SII). MATERIAL AND METHODS: The advanced epidermal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
